STOCK TITAN

Inhibitor Therapeutics (INTI) holder makes 3.2M-share gift

(Neutral)
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Black Robe Capital LLC, a 10% owner of Inhibitor Therapeutics, Inc., together with Chief Financial Officer James A. McNulty as reporting persons, recorded a bona fide gift of 3,200,000 shares of common stock on July 1, 2026. Following this disposition, the reporting holder directly owned 19,901,057 common shares.

Positive

  • None.

Negative

  • None.
Insider Black Robe Capital LLC, MCNULTY JAMES A
Role 10% Owner | Chief Financial Officer
Type Security Shares Price Value
Gift Common Stock 3,200,000 $0.00 $0.00
Holdings After Transaction: Common Stock — 19,901,057 shares (Direct)
Gifted shares 3,200,000 shares Bona fide gift of common stock on July 1, 2026
Transaction price per share $0.0000 Reported per-share price for the gifted shares
Shares owned after transaction 19,901,057 shares Direct common stock holdings following the gift
Gift transactions 1 Number of bona fide gifts reported in this Form 4
Total gift shares (summary) 3,200,000 shares Gift shares reported in the transaction summary
bona fide gift financial
"The transaction code G was described as a bona fide gift."
A bona fide gift is a genuine, voluntary transfer of money, property, or benefits from one party to another made without expectation of repayment, services, or hidden conditions. Investors care because such gifts can affect company disclosures, related‑party transaction rules, tax treatment, and perceived conflicts of interest; think of it like someone giving you a present with no strings attached — but on a corporate scale, auditors and regulators need to verify it really is unconditional.
ten percent owner financial
"Black Robe Capital LLC was identified as a ten percent owner."
Common Stock financial
"The reported transaction involved shares of Common Stock."
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What insider transaction did Inhibitor Therapeutics (INTI) report in this Form 4?

Inhibitor Therapeutics insiders reported a bona fide gift of 3,200,000 common shares. The transaction involved a disposition coded as “G,” indicating a gift transfer of stock rather than an open-market sale or purchase, and carried a reported price of $0.0000 per share.

When did the 3,200,000-share gift for Inhibitor Therapeutics (INTI) occur?

The gift transaction occurred on July 1, 2026. On that date, a reporting holder transferred 3,200,000 shares of Inhibitor Therapeutics common stock as a bona fide gift, with no cash consideration reflected in the reported per-share transaction price of $0.0000.

Who are the reporting persons in the Inhibitor Therapeutics (INTI) insider gift filing?

The reporting persons are Black Robe Capital LLC, identified as a ten percent owner, and James A. McNulty, the company’s Chief Financial Officer. They jointly reported the bona fide gift of 3,200,000 common shares of Inhibitor Therapeutics, Inc.

How many Inhibitor Therapeutics (INTI) shares were held after the gift transaction?

After the bona fide gift of 3,200,000 shares, the reporting holder directly owned 19,901,057 shares of common stock. This post-transaction figure reflects the remaining direct holdings reported for the same class of Inhibitor Therapeutics equity securities.

Was the Inhibitor Therapeutics (INTI) insider gift under a Rule 10b5-1 trading plan?

The gift was not reported as made under a Rule 10b5-1 trading plan. The Rule 10b5-1 checkbox was left unmarked, indicating the disposition of 3,200,000 shares as a bona fide gift was not designated as pursuant to a pre-arranged trading arrangement.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Black Robe Capital LLC

(Last)(First)(Middle)
C/O INHIBITOR THERAPEUTICS, INC.,
3014 WEST PALMIRA AVE SUITE 302

(Street)
TAMPA FLORIDA 33629

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Inhibitor Therapeutics, Inc. [ INTI ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
DirectorX10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/01/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
Form filed by One Reporting Person
XForm filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock07/01/2026G3,200,000D$019,901,057D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
1. Name and Address of Reporting Person*
Black Robe Capital LLC

(Last)(First)(Middle)
C/O INHIBITOR THERAPEUTICS, INC.,
3014 WEST PALMIRA AVE SUITE 302

(Street)
TAMPA FLORIDA 33629

(City)(State)(Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
MCNULTY JAMES A

(Last)(First)(Middle)
C/O INHIBITOR THERAPUTICS, INC.,
3014 WEST PALMIRA AVE SUITE 302

(Street)
TAMPA FLORIDA 33629

(City)(State)(Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Financial Officer
Explanation of Responses:
/s/ James A. McNulty08/04/2026
/s/ James A. McNulty, Manager of Balckrobe Capital, LLC08/04/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)